DWA
TCRT icon

Dorsey Wright & Associates’s Alaunos Therapeutics TCRT Stock Holding History

Dorsey Wright & Associates’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-16
Closed -$14K – 329
2019
Q2 		$14K Buy
+16
New +$11K ﹤0.01% 185

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Dorsey Wright & Associates's TCRT Position: Q3 2019 in Review

Dorsey Wright & Associates sold out of Alaunos Therapeutics (TCRT) in Q3 2019, closing a stake of 16 shares — an estimated $14K sold.

Dorsey Wright & Associates first reported a position in TCRT in Q2 2019 and held it in 1 quarter. The position peaked at $14K in Q2 2019. 142 funds tracked by Wall St. Rank hold TCRT as of Q3 2019.

  • Dorsey Wright & Associates reported no remaining Alaunos Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 16 Alaunos Therapeutics shares in Q3 2019, an estimated $14K.
  • Dorsey Wright & Associates first reported a position in Alaunos Therapeutics in Q2 2019 and held it in 1 quarter.
  • Dorsey Wright & Associates's Alaunos Therapeutics position peaked at $14K in Q2 2019.
  • 142 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2019.

Based on Dorsey Wright & Associates's 13F filing for Q3 2019, filed 31 Oct 2019.